To determine whether sulindac and its metabolites could modulate NQO1 expression in lung cancer cell lines, they were used at concentrations of 100 and 250 μM to treat CL1-1 and CL1-5 cells for 6, 12, or 24 h. This evidence concerns the gene NQO1 and lung carcinoma.